stockrow
Monday 9 November 2026
Export KROS’s income statement to Excel — free account
Keros Therapeutics, Inc.
KROSKeros Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $244.1 million, up 6,775.0% from fiscal 2024.
- Revenue
- +120.2%
- EPS
- +494.4%
- Free cash flow
- +6.87%
Quarter to September 2026, against a year earlier
9.36
0.09
−0.95%
Follow KROS
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | — | 0.00 | 10.95 |
+8 more quarters Free account |
P/S ratio |
4.12 | — | 6.53 | 3.11 | |
P/FCF ratio |
0.00 | — | 0.00 | 7.15 | |
P/Operating CF |
66.87 | — | (61.41) | (27.77) | |
P/B ratio |
0.81 | — | 0.76 | 2.50 | |
Price to Tangible BV |
0.81 | — | 0.76 | 2.50 | |
EV/Sales |
(0.60) | — | (1.95) | 1.93 | |
EV/EBITDA |
0.46 | — | 0.60 | 6.81 | |
EV/Operating CF |
0.68 | — | 1.13 | 4.38 | |
EV/FCF |
0.68 | — | 1.11 | 4.44 | |
Quick Ratio |
16.36 | 21.38 | 22.11 | 14.36 | |
Current Ratio |
18.14 | 21.96 | 22.62 | 15.45 | |
Net Debt/EBITDA |
(19.65) | 8.44 | 11.05 | 9.96 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.10 | 0.00 | 0.06 | 0.51 | |
Operating CF/Net income |
0.24 | 0.71 | 0.15 | 1.16 | |
Capex/Depreciation |
(0.15) | (0.39) | (0.18) | (0.33) | |
Research and Development Expense of Revenue |
51.22% | 0.00% | 4,386.10% | 4,652.47% | |
Selling, General and Administrative Expense of Revenue |
16.75% | 0.00% | 2,764.85% | 3,050.13% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
10.51% | 0.00% | 1,689.10% | 1,897.40% | |
Graham Net Nets |
1.14 | — | 1.22 | 0.37 | |
Graham Number |
0.00 | — | 0.00 | 18.46 | |
Earnings Yield |
(24.65%) | — | (27.26%) | 9.14% | |
Free Cash Flow Yield |
(21.29%) | — | (26.88%) | 13.98% | |
Revenue per Share |
2.01 | 0.00 | 0.02 | 0.01 | |
Operating CF per Share |
0.17 | (1.03) | (0.18) | (0.73) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.17 | (1.04) | (0.18) | (0.74) | |
Cash per Share |
13.05 | 13.01 | 14.34 | 7.72 | |
Shareholders Equity per Share |
14.03 | 13.25 | 14.55 | 8.14 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
14.03 | 13.25 | 14.55 | 8.14 | |
Free Cash Flow |
3.33 | (20.58) | (3.60) | (27.43) | |
Working Capital |
271.78 | 254.73 | 277.82 | 295.02 | |
Capital Expenditures |
(0.06) | (0.15) | (0.07) | (0.13) | |
Net Current Asset Value |
259.36 | 241.60 | 264.01 | 280.55 | |
EV/EBIT |
0.45 | — | 0.59 | 6.96 | |
Capex to Sales |
0.00 | 0.00 | 0.20 | 0.35 | |
Price to Operating Income |
0.00 | — | 0.00 | 11.22 | |
| Other line items | |||||
Average Receivables |
— | 9.03 | 9.97 | 4.28 | |
Average Payables |
3.04 | 3.54 | 4.06 | 3.28 | |
Average Assets |
525.08 | 522.38 | 548.43 | 476.95 | |
Average Common Equity |
491.34 | 484.53 | 507.25 | 437.34 |
Columns are period end dates · fundamentals updated 5 Nov 2026